EPI-002

EPI-002

EPI-002 is a second-generation antiandrogen that has been studied for its potential use in the treatment of prostate cancer. It is a derivative of EPI-001, which was the first compound identified in the EPI series. EPI-002 works by inhibiting the androgen receptor (AR), a critical driver of prostate cancer progression.

Mechanism of Action

EPI-002 functions by binding to the androgen receptor at a site distinct from the ligand-binding domain. This unique mechanism allows it to inhibit the AR even in cases where the receptor has become resistant to other forms of antiandrogen therapy, such as enzalutamide and abiraterone. By preventing the AR from activating target genes, EPI-002 can effectively reduce the growth and proliferation of prostate cancer cells.

Development and Research

EPI-002 is part of a broader class of drugs known as AR N-terminal domain inhibitors. These inhibitors are designed to target the N-terminal domain of the AR, which is essential for its transcriptional activity. The development of EPI-002 and related compounds represents a significant advancement in the treatment of castration-resistant prostate cancer (CRPC), a form of the disease that no longer responds to traditional androgen deprivation therapy.

Clinical Trials

As of the latest updates, EPI-002 has undergone preclinical studies demonstrating its efficacy in inhibiting AR activity and reducing tumor growth in animal models. Clinical trials are anticipated to further evaluate its safety and effectiveness in human patients with advanced prostate cancer.

Related Compounds

EPI-002 is closely related to other compounds in the EPI series, including EPI-001 and EPI-506. These compounds share a similar mechanism of action but may differ in their pharmacokinetic properties and clinical efficacy.

See Also

• Prostate cancer
• Androgen receptor
• Castration-resistant prostate cancer
• Androgen deprivation therapy
• Enzalutamide
• Abiraterone
• EPI-001
• EPI-506

External Links

-